Grifols board member says response to market regulator imminent
19 Jan 2024
Acquisition
The logo of the Spanish pharmaceuticals company Grifols is pictured on theirs facilities in Parets del Valles, north of Barcelona, Spain, January 9, 2024. REUTERS/Albert Gea/File Photo Acquire Licensing Rights, opens new tab
Reporting by Joan Faus, additional reporting by Jesús Aguado, Tiago Brandao and Matteo Allievi, editing by Inti Landauro, David Latona and Barbara Lewis
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Preview
Source: Reuters
Thomson Reuters
Joan is a Barcelona-based correspondent reporting on politics, economics and social issues, such as migration and the car industry’s green transition, and also conducting investigative pieces. With over 15 years of experience, Joan previously worked as Washington correspondent for Spain’s leading newspaper EL PAÍS, closely covering the Obama and Trump administrations, electoral campaigns and major news; at Spanish newspapers Ara and Público in Madrid, and at EFE news agency in Buenos Aires and Barcelona. He is a journalism graduate from Barcelona’s Autonomous University, including an exchange program in Amsterdam and New York, and holds a business executive degree from IESE Business School
Preview
Source: Reuters
Preview
Source: Reuters
Preview
Source: Reuters
Preview
Source: Reuters
Preview
Source: Reuters
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.